Posts

Debate from Arendalsuka

Together for precision medicine

During Arendalsuka 2019, we arranged a breakfast meeting on the development of cancer treatments of the future, together with LMI and Kreftforeningen.

Arendalsuka has become an important arena for those who want to improve aspects of Norwegian society. We were there this year to meet key players to accelerate the development of cancer treatments.

Our main event of the week was a collaboration with Legemiddelindustrien (LMI) and The Norwegian Cancer Society (Kreftforeningen). We wanted to highlight the cancer treatments of the future and whether Norway is equipped to keep up with the rapid developments in precision medicine. (Read a summary of the event in Norwegian on LMI’s website)

First speaker, Line Walen (LMI), presented the problems with the traditional system for approving new treatments in face of precision medicine.

The second presenter, Kjetil Taskén (Oslo University Hospital), introduced their new plan at Oslo University Hospital to implement precision medicine.

Then, Steinar Aamdal (University of Oslo) talked about what we can learn from Denmark when implementing precision medicine.

Lastly, Ole Aleksander Opdalshei (Norwegian Cancer Society) highlighted a new proposal for legislation from the government.

The exciting program was followed by a lively discussion between both politicians and cancer experts.

There was general agreement in the panel that developments are not happening fast enough and that the Norwegian health infrastructure and system for approving new treatments is not prepared to handle precision medicine, even though cancer patients need it immediately.

The panelists proposed some possible solutions:

  • Better collaboration and public-private partnerships between the health industry and the public health sector.
  • More resources to improve the infrastructure for clinical trials, with both staff, equipment and financial incentives.
  • Better use of the Norwegian health data registries.

After the debate, we interviewed a few of the participants and attendees. We asked: which concrete measures are needed for Norway to get going with precision medicine?

Watch the six-minute video below (in Norwegian) to find out what they said. (Turn up the sound)

 

Did you miss the meeting? View the whole video below on YouTube (in Norwegian).

 

Full list of participants:

  • Wenche Gerhardsen, Head of Communications, Oslo Cancer Cluster (Moderator)
  • Line Walen, Senior Adviser, LMI
  • Kjetil Taskén, director Institute for Cancer Research, Oslo University Hospital
  • Steinar Aamdal, professor emeritus, University of Oslo
  • Ole Aleksander Opdalshei, assisting general secretary, The Norwegian Cancer Society
  • Marianne Synnes (H), politician
  • Geir Jørgen Bekkevold (KrF), politician
  • Tuva Moflag (Ap), politician
  • Per Morten Sandset, vice principal for Innovation, University of Oslo
  • Audun Hågå, Director Norwegian Medicines Agency

 

Thank you to all participants and attendees!

The next event in this meeting series will take place in Oslo in the beginning of next year. More information will be posted closer to the event.

We hope to see you again!

 

Organisers:

 

 

 

 

 

Sponsors:

 

Dr James Allison, Dr Padmanee Sharma

Nobel Prize winner joins Lytix Biopharma

The Nobel Laureate Dr James Allison and oncologist Dr Padmanee Sharma will become strategic advisors for our member Lytix BioPharma.

Oslo Cancer Cluster’s member Lytix BioPharma announced this week that the cancer researchers and married couple Dr James Allison (PhD) and Dr Padmanee Sharma (MD) will join their Scientific Advisory Board.

Dr James Allison was, together with Dr Tasuku Honjo, awarded the 2018 Nobel Prize in Medicine last December. The renowned cancer researchers received the award for their ground-breaking work in immunology. It has become the basis for different immunotherapies, an area within cancer therapy that aims to activate the patient’s immune system to fight cancer.

Dr Sharma is a distinguished oncologist, who has focused her work on understanding different resistant mechanisms in the immune system. These resistant mechanisms sometimes hinder immunotherapies from working on every cancer tumour and every cancer patient.

Lytix Biopharma is a biotech company, located in the Oslo Cancer Cluster Incubator, that develops novel cancer immunotherapies. They are making an “oncolyctic peptide” – a drug with the potential to personalize every immunotherapy to fit each patient.

  • Please visit Lytix BioPharma’s official website for more information about their product

Edwin Clumper, CEO of Lytix BioPharma, expressed how thrilled he was to welcome Dr Allison and Dr Sharma:

“We are honoured that they have offered their support to further the development of our oncolytic peptides with the aim to tackle tumour heterogeneity – an unresolved challenge in cancer treatment.”

 

Sign up to OCC newsletter

A successful first quarter for Nordic Nanovector

Nordic Nanovector raises NOK 225 million in private placements, begins phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company. These were some of the good news presented in the first quarter 2019 report.

Oslo Cancer Cluster’s member company Nordic Nanovector develops precision medicine against haematological cancers. These are the types of cancers affecting blood, bone marrow and lymph nodes – also known as leukaemia, lymphoma and myeloma. These cancers are notoriously difficult to treat and therefore have a highly unmet medical need.

On the morning of 23 May 2019, the CEO of Nordic Nanovector, Eduardo Bravo, presented some of the successes the company has had during the first quarter of 2019.

“As we advance the clinical development programmes with Betalutin, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner.”

The company’s highlights from the first quarter included raising approximately NOK 225 million in private placements.

They have also extended their clinical trials, known as the PARADIGME study, which address advanced, recurring follicular lymphoma. They now have phase II clinical trials in over 74 sites in 23 countries.

During the first quarter, Nordic Nanovector has also welcomed a new chairman to the Board of Directors – Jan H. Egberts, M.D. He is also the chairperson of the Board of Directors of Oslo Cancer Cluster member Photocure.

Lastly, Dr Mark Wright has been appointed Head of Manufacturing to lead the production of Nordic Nanovector’s therapies. This prepares Nordic Nanovector for future commercialisation and will hopefully lead to more precise treatments successfully reaching cancer patients.